Fibroscan Market Research Report Information By Technology (Vibration-controlled Transient Electrography (VCTE), Controlled Attenuation Parameter (CAP) and Others), By Modality (Portable and Non-Portable/Standalone), By Application (Hepatitis B or C, Nonalcoholic Fatty Liver Disease, Alcohol-related Liver Problems, Hemochromatosis and Others), By End-user (Hospitals & Clinics, Diagnostic Centers, Ambulatory Surgical Centers and Others), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2032

Global Fibroscan Market Overview

The Fibroscan Market Size was valued at USD 93.1 Billion in 2023. The Fibroscan market industry is projected to grow from USD 97.8 Billion in 2024 to USD 137.6 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.00% during the forecast period (2024 - 2032). Growing awareness and screening programs are the key market drivers enhancing market growth.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Fibroscan Market Trends

• 
  

  Growing awareness and screening programs are driving market growth

  
  

Market CAGR for Fibroscan is being driven by the growing awareness and screening programs. In the ever-evolving landscape of healthcare, where the drums of awareness campaigns incessantly beat against the backdrop of high-risk populations, and the clarion call of healthcare providers resounds, resonating with the imperative of liver health, a crescendo of recognition rises. Its crescendos into a symphony of necessity, wherein the need for non-invasive diagnostic methodologies like Fibroscan becomes not just apparent but exigent. These campaigns, akin to heralds of proactive healthcare, beckon individuals to embark on the journey of self-awareness, urging them to seek the sanctuary of liver health assessments. As the tides of awareness swell, they forge alliances, knitting together the sinews of healthcare organizations and diagnostic centers. Together, they erect bridges of accessibility, spanning across the chasm that once divided individuals from the realms of screening services. It is this convergence of forces, this nexus of endeavors, that propels the chariot of Fibroscan into the hearts and minds of the populace.

It is the specter of liver diseases that looms large over the horizon of global health. Hepatitis, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and the insidious tendrils of liver fibrosis writhe and writhe, tightening their grip upon humanity. They are the harbingers of affliction, borne upon the winds of obesity, the tempests of unhealthy lifestyles, the contagion of viral infections, and the siren call of alcohol.

Increasing healthcare expenditure globally is a significant driver of the Fibroscan Market. As governments and healthcare organizations allocate more resources towards improving healthcare infrastructure and services, there is greater emphasis on investing in advanced diagnostic technologies like Fibroscan. The rising healthcare expenditure enables healthcare facilities to procure Fibroscan devices, which offer non-invasive and accurate assessment of liver health. Moreover, increased funding for healthcare services allows for the expansion of screening and monitoring programs for liver diseases, which further drives the demand for Fibroscan technology. Additionally, with higher healthcare spending, there is greater accessibility to Fibroscan services for patients, leading to increased adoption of this innovative diagnostic tool. Consequently, the escalating healthcare expenditure worldwide acts as a catalyst for the growth and expansion of the Fibroscan Market. For instance, Boehringer Ingelheim announced the initiation of clinical development for its novel IL-11 inhibitor antibody, BI 765423, with a Phase 1 study (NCT05658107) aimed at assessing safety, tolerability, and pharmacokinetics in healthy volunteers. Preclinical research has indicated that anti-IL-11 therapy could potentially impede and even reverse fibrosis across various fibrotic conditions.

Fibroscan Market Segment Insights

Fibroscan Technology Insights

The Fibroscan market segmentation, based on technology, includes vibration-controlled transient electrography (VCTE), controlled attenuation Parameters (CAP), and others. In 2023, the Vibration-controlled transient electrography (VCTE) segment dominated the market, accounting for 35% of market revenue. VCTE technology offers a reliable and non-invasive method for assessing liver fibrosis, attracting healthcare providers and patients seeking accurate diagnostic tools with minimal discomfort. Moreover, VCTE technology has undergone extensive clinical validation, demonstrating high accuracy and reliability in liver stiffness measurement. Additionally, the widespread adoption of VCTE devices by healthcare facilities further solidifies its dominance in the market.

Controlled Attenuation Parameter (CAP) Technology is experiencing the highest Compound Annual Growth Rate (CAGR) in the Fibroscan Market due to several factors. CAP technology provides additional value by assessing liver steatosis alongside fibrosis, addressing the growing need for comprehensive liver assessment. With rising awareness of liver diseases, there's an increased demand for advanced diagnostic tools like CAP Fibroscan. Moreover, ongoing technological advancements improving CAP accuracy and usability further drive its adoption, positioning it for rapid growth in the market.

Fibroscan Modality Insights

The global Fibroscan market segmentation, based on Modality, includes Portable and Non-Portable/Standalone. In 2023, the Portable category generated the most income due to its convenience and versatility. Portable Fibroscan devices offer healthcare providers the flexibility to perform assessments in various clinical settings, including clinics, hospitals, and remote locations. Additionally, portable devices cater to the growing demand for point-of-care diagnostics, enabling timely assessments and interventions. Moreover, advancements in portable device technology, such as improved accuracy and user-friendliness, further contribute to their widespread adoption, solidifying their dominance in the market.

The Non-Portable/Standalone Modality is experiencing the highest Compound Annual Growth Rate (CAGR) in the Fibroscan Market due to several factors. While portable devices offer convenience, standalone Fibroscan systems are preferred in settings where dedicated diagnostic facilities are available, such as specialized clinics and hospitals. The growing demand for comprehensive liver assessments in these settings, coupled with advancements in standalone device technology improving accuracy and reliability, drives their adoption and positions them for rapid growth in the market.

Figure 1: Global Fibroscan Market, by Modality, 2023 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Fibroscan Application Insights

The global Fibroscan market segmentation, based on Application, includes Hepatitis B or C, Nonalcoholic fatty liver disease, Alcohol-related liver problems, Hemochromatosis, and Others. In 2023, the Hepatitis B or C category generated the most income. Hepatitis B and C infections are leading causes of liver fibrosis and cirrhosis, necessitating frequent liver assessments for disease staging and monitoring. Fibroscan technology provides a non-invasive and accurate method for evaluating liver fibrosis, making it indispensable in the management of these infections. Moreover, ongoing advancements in Fibroscan devices tailored for hepatitis B and C applications further contribute to their widespread adoption, solidifying their dominance in the market.

The Nonalcoholic Fatty Liver Disease (NAFLD) application is experiencing the highest Compound Annual Growth Rate (CAGR) in the Fibroscan Market due to several key factors. NAFLD is becoming increasingly prevalent globally due to rising obesity rates and unhealthy lifestyles. Fibroscan technology offers a non-invasive and reliable method for assessing liver fibrosis and steatosis, which is essential for diagnosing and monitoring NAFLD progression. Additionally, growing awareness of NAFLD-related complications and the importance of early detection drive the demand for Fibroscan devices tailored for NAFLD applications, positioning them for rapid growth in the market.

Fibroscan End-User Insights

The global Fibroscan market segmentation, based on End-User, includes Hospitals & Clinics, Diagnostic Centers, Ambulatory Surgical Centers, and Others. In 2023, the Hospitals & Clinics category generated the most income. These healthcare facilities serve as primary points of care for patients with liver diseases, where timely diagnosis and monitoring are crucial. Fibroscan technology provides a non-invasive and efficient method for assessing liver health, making it indispensable in hospital and clinic settings. Additionally, the availability of skilled healthcare professionals and infrastructure supports the integration and utilization of Fibroscan devices, solidifying their dominance in the market.

Diagnostic center end-users are experiencing the highest Compound Annual Growth Rate (CAGR) in the Fibroscan Market due to several factors. Diagnostic centers offer specialized services focused on liver health assessment, attracting patients seeking comprehensive diagnostic evaluations. Fibroscan technology's non-invasive nature and accurate results make it particularly suitable for diagnostic center settings. Additionally, the increasing prevalence of liver diseases and the growing demand for advanced diagnostic tools drive the adoption of Fibroscan devices in diagnostic centers, positioning them for rapid growth in the market.

Fibroscan Regional Insights

By region, the study provides the market insights into North America, Europe, Asia-Pacific, and the Rest of the World. North America has secured the largest market share in the Fibroscan Market due to several key factors. The region boasts advanced healthcare infrastructure, a high prevalence of liver diseases, and robust research and development activities. Moreover, favorable reimbursement policies and regulatory frameworks support the adoption of Fibroscan technology in clinical practice. Additionally, increasing awareness about liver diseases and early detection initiatives further drive the demand for Fibroscan devices in North America, solidifying its dominance in the market.

Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, and South Korea.

Figure 2: Global Fibroscan Market Share By Region 2023 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe Fibroscan market accounts for the second-largest market share due to the high prevalence of liver diseases. Europe has secured the second-largest market share in the Fibroscan Market due to several factors. The region benefits from a well-established healthcare system, a high prevalence of liver diseases, and increasing awareness about non-invasive diagnostic methods. Moreover, supportive regulatory policies and favorable reimbursement schemes encourage the adoption of Fibroscan technology in clinical practice. Additionally, ongoing research and development efforts and collaborations between healthcare institutions drive innovation and market growth, positioning Europe as a key market player in Fibroscan technology adoption. Further, the German Fibroscan market held the largest market share, and the UK Fibroscan market was the fastest growing market in the European region.

The Asia-Pacific Fibroscan Market is expected to grow at the fastest CAGR from 2024 to 2032. The Asia Pacific region is experiencing the highest Compound Annual Growth Rate (CAGR) in the Fibroscan Market due to several key factors. These include a rising prevalence of liver diseases, increasing healthcare infrastructure development, and growing awareness about non-invasive diagnostic methods. Additionally, expanding healthcare expenditure and supportive government initiatives drive the adoption of Fibroscan technology in the region. Moreover, the presence of a large population and untapped market potential contribute to the rapid growth of the Fibroscan Market in Asia Pacific. Moreover, China’s Fibroscan market held the largest market share, and the Indian Fibroscan market was the fastest growing market in the Asia-Pacific region.

Fibroscan Key Market Players & Competitive Insights

Leading players in the Fibroscan Market are focused on strategic initiatives to maintain their market position and drive growth. This includes investments in research and market developments to enhance Fibroscan technology, expand product portfolios, and improve diagnostic accuracy. Additionally, partnerships, collaborations, mergers, and acquisitions are pursued to broaden market reach, access new geographic regions, and strengthen distribution networks. Moreover, marketing campaigns, educational initiatives, and customer support services are employed to increase awareness and promote the adoption of Fibroscan technology.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global Fibroscan industry to benefit clients and increase the market sector. In recent years, the Fibroscan industry has offered some of the most significant advantages to Portable. Major players in the Fibroscan market, including Echosens, Siemens Healthineers, GE Healthcare, Philips Healthcare, Canon Medical Systems Corporation, Hitachi Medical Systems, Mindray Medical International Limited, Samsung Medison, FibroScan, Resoundant, Inc., and Others, are attempting to increase market demand by investing in research and development operations.

Echosens is a prominent player in the Fibroscan Market, specializing in innovative medical devices for non-invasive liver assessment. The company's flagship product, FibroScan, utilizes Vibration-Controlled Transient Elastography (VCTE) and Controlled Attenuation Parameter (CAP) technologies to assess liver stiffness and fat content, providing valuable diagnostic information for liver diseases. Echosens is committed to advancing liver health through accurate and accessible diagnostic solutions, catering to healthcare providers worldwide. With a focus on research and development, Echosens continuously strives to enhance FibroScan technology, improve diagnostic accuracy, and expand applications across various liver conditions. Moreover, the company offers comprehensive training, support, and service solutions to ensure optimal utilization and customer satisfaction, solidifying its position as a leading provider in the Fibroscan Market.

GE Healthcare is a prominent player in the Fibroscan Market, offering innovative medical imaging and diagnostic solutions worldwide. While not a direct provider of Fibroscan technology, GE Healthcare manufactures and distributes a wide range of medical devices and equipment used in liver imaging and assessment, including ultrasound systems and advanced imaging modalities. Leveraging its extensive expertise in medical imaging, GE Healthcare collaborates with other companies developing Fibroscan technology, providing essential infrastructure and support for liver assessment procedures. With a commitment to advancing healthcare through technological innovation, GE Healthcare plays a significant role in facilitating the adoption and utilization of Fibroscan devices, contributing to improved patient care and outcomes in the Fibroscan Market.

Key Companies in the Fibroscan market include

• Echosens


• Siemens Healthineers


• GE Healthcare


• Philips Healthcare


• Canon Medical Systems Corporation


• Hitachi Medical Systems


• Mindray Medical International Limited


• Samsung Medison


• FibroScan


• Resoundant, Inc.

Fibroscan Industry Developments

March 2022: Echosens introduced FibroScan GO, an economical and efficient liver health screening tool, in the United Kingdom.

January 2022: Siemens Healthineers introduced the Enhanced Liver Fibrosis (ELF) Test in the United States, marking the first and sole prognostic blood test granted De Novo marketing authorization for evaluating disease progression in individuals with non-alcoholic steatohepatitis (NASH).

Fibroscan Market Segmentation

Fibroscan Technology Outlook

• Vibration-controlled transient electrography (VCTE)


• Controlled Attenuation Parameter (CAP)


• Others

Fibroscan Modality Outlook

• Portable


• Non-Portable/Standalone

Fibroscan Application Outlook

• Hepatitis B or C


• Nonalcoholic fatty liver disease


• Alcohol-related liver problems


• Hemochromatosis


• Others

Fibroscan End-User Outlook

• Hospitals & Clinics


• Diagnostic Centers


• Ambulatory Surgical Centers


• Others

Fibroscan Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America